Pharmaceutical Investing AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pharmaceutical Investing Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid Injectable Fillers
Pharmaceutical Investing Health Canada Approves ELAHERE® for Certain Types of Platinum-Resistant Ovarian Cancers
Pharmaceutical Investing AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Pharmaceutical Investing RINVOQ® Receives Health Canada Notice of Compliance for Giant Cell Arteritis in adults
Pharmaceutical Investing AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
Pharmaceutical Investing AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib for Alopecia Areata
Pharmaceutical Investing AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
CORRECTED: CHARBONE Hydrogen is Acquiring Hydrogen Production Assets and Closing a First Tranche of $1M Private Placement Financing
CORRIGE: CHARBONE Hydrogene acquiert des actifs de production d'hydrogene et cloture une premiere tranche d'un financement par placement prive de 1 M$
